News | Nanologica

Bokslutskommuniké 2025 Nanologica AB (publ)

26 February, 2026

FINANSIELL SAMMANFATTNING Nettoomsättningen för fjärde kvartalet uppgick till 5 205 TSEK (6 715) och för helåret till 21 127 TSEK (14 538) Rörelseresultatet för kvartalet uppgick till -15 706 TSEK (-11 890) och för helåret till -46 801 TSEK (-59 255) Resultatet efter skatt för kvartalet uppgick till -16 733 TSEK (-14 033) och för helåret till -51 289 TSEK (-65 629) Resultat per aktie före och efter utspädning var -0,19 SEK (-0,19) för kvartalet och

Year-End Report 2025 Nanologica AB (publ)

26 February, 2026

FINANCIAL SUMMARY Net sales for the fourth quarter amounted to SEK 5,205 thousand (6,715) and for the full year to SEK 21,127 thousand (14,538) Operating loss for the quarter amounted to SEK -15,706 thousand (-11,890) and for the full year to SEK -46,801 thousand (-59,255) Loss after tax for the quarter amounted to SEK -16,733 thousand (-14,033) and for the full year to SEK -51,289 thousand (-65,629) Earnings per share before and after dilution were

Jeremie Trochu föreslås som ny styrelseledamot i Nanologica AB (publ)

10 February, 2026

Ardena-koncernens vd Jeremie Trochu föreslås som ny styrelseledamot i Nanologica AB. Förslaget har lagts fram av Nanologicas huvudägare Flerie Invest AB i samband med Nanologicas förvärv av Ardena Södertälje AB. Förslaget kommer att behandlas vid den extra bolagsstämman den 4 mars. Förslaget att välja in Jeremie Trochu i Nanologicas styrelse markerar fortsatt samarbete mellan Nanologica och Ardena efter att Nanologica förvärvat Ardena Södertälje (numera Syntagon) ur Ardenakoncernen. Bolagen avser framför allt att samarbeta kring gemensamma

Jeremie Trochu Proposed as New Board Member of Nanologica AB (publ)

10 February, 2026

Jeremie Trochu, CEO of the Ardena Group, is proposed as a new member of the board of directors of Nanologica AB. The proposal has been presented by Nanologica's main owner Flerie Invest AB in connection with Nanologica's acquisition of Ardena Södertälje AB. The proposal will be resolved at the Extraordinary General Meeting on March 4. The proposal to elect Jeremie Trochu to Nanologica's board of directors marks the continued collaboration between Nanologica and Ardena after

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

30 January, 2026

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma onsdagen den 4 mars 2026, klockan 10.00, i Advokatfirman Lindahls lokaler, på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 24 februari 2026, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast torsdagen den 26

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

30 January, 2026

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby invited to attend the Extraordinary General Meeting to be held on Wednesday, March 4, 2026, at 10.00 a.m. CET at Advokatfirman Lindahl's premises, at Smålandsgatan 16, Stockholm. Right to participate in the meeting Shareholders who wish to participate in the Extraordinary General Meeting must: be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on Tuesday,

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.